United Bank (Virginia)’s Lineage Cell Therapeutics LCTX Stock Holding History

United Bank (Virginia)’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$27.7K	Buy	+21,170	New	+$29.3K	﹤0.01%	130
2025 Q1	–	Sell	-12,000	Closed	-$6.03K	–	143
2024 Q4	$6.03K	Sell	12,000 -40,000	-77%	-$29.4K	﹤0.01%	134
2024 Q3	$47.1K	Hold	52,000	–	–	0.01%	137
2024 Q2	$51.9K	Buy	52,000 +10,000	+24%	+$11K	0.01%	136
2024 Q1	$62.2K	Buy	42,000 +12,200	+41%	+$13.8K	0.01%	143
2023 Q4	$32.5K	Hold	29,800	–	–	﹤0.01%	143
2023 Q3	$35.2K	Buy	29,800 +4,200	+16%	+$5.71K	﹤0.01%	142
2023 Q2	$36.1K	Buy	+25,600	New	+$35.4K	﹤0.01%	150

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

United Bank (Virginia)'s LCTX Position: Q2 2026 in Review

United Bank (Virginia) opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 21,170 shares worth $27.7K. The stake represents ﹤0.01% of the portfolio and ranks #130 among its holdings. This is a return to the name: United Bank (Virginia) previously reported a position in LCTX as recently as Q4 2024.

United Bank (Virginia) first reported a position in LCTX in Q2 2023 and has held it in 8 quarters since. The position peaked at $62.2K in Q1 2024. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

United Bank (Virginia) held 21,170 shares of Lineage Cell Therapeutics worth $27.7K as of Q2 2026.
Lineage Cell Therapeutics was a new United Bank (Virginia) position in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of United Bank (Virginia)'s portfolio in Q2 2026, its #130 holding.
United Bank (Virginia) first reported a position in Lineage Cell Therapeutics in Q2 2023 and has held it in 8 quarters since.
United Bank (Virginia)'s Lineage Cell Therapeutics position peaked at $62.2K in Q1 2024.
132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on United Bank (Virginia)'s 13F filing for Q2 2026, filed 30 Jul 2026.